Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T21:07:59.335Z Has data issue: false hasContentIssue false
  • English
  • Français

Lipid-lowering drugs and violence

Published online by Cambridge University Press:  02 January 2018

David F. Horrobin
David F. Horrobin*
Affiliation:
Efamol Research Institute, PO Box 818, Kentville, Nova Scotia, Canada B4N 4H8
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
The British Journal of Psychiatry , Volume 154 , Issue 6 , June 1989 , pp. 882 - 883
Copyright
Copyright © Royal College of Psychiatrists, 1989 

References

Frick, M. H., Elo, O., Haapa, K. et al (1987) Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New England Journal of Medicine, 317, 1237–1245.Google Scholar
Lipid Research Clinics Program (1984) The Lipid Research Clinics coronary primary prevention trial results. Journal of the American Medical Association, 251, 351–364.Google Scholar
Virkkunen, M. (1983) Serum cholesterol levels in homicidal offenders. Neuropsychobiology, 10, 65–69.Google Scholar
Virkkunen, M. & Pentttnen, H. (1984) Serum cholesterol in aggressive conduct disorder. Biological Psychiatry, 19, 435–439.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.